Law firms Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’ Sophie Chan · 9 February 2024 · 3 min read Profile Life Sciences Yearbook 2024 McDermott Will & Schulte David Gibson, senior associate at McDermott Will & EmeryWhy did you decide to specialise in life sciences law, and what’s the best thing about being a life sciences lawyer?This article is for Legal Business subscribers. Please log in or subscribe to read on. Related ContentMore in this categoryMcDermott partner promotions halve as London promotions tick upLaw firmsKate Peacock26 Oct 2026US firms bump City trainee pay to £75kLaw firmsKate Peacock23 Oct 2026US firms lead as LSEG acquires Octus from Permira for $3.5bnLaw firmsWill Lewallen22 Oct 2026M&A perspectives: Melissa FogartyLaw firmsIman Tribak26 Jun 2024M&A perspectives: Jennifer BethlehemLaw firmsIman Tribak26 Jun 2024M&A perspectives: Lorenzo CorteLaw firmsIman Tribak26 Jun 2024Sponsored thought leadership: China life sciences – Transaction insights and notable industry trendsPractice areasGuest Blog9 Feb 2024The Legal 500 view: Healthy competitionLaw firmsBen Wheway9 Feb 2024Life Sciences Yearbook 2024 – Editor’s letterPractice areasGeorgina Stanley9 Feb 2024